Commentary: advances in the pharmacotherapy of NASH-anti-diabetic drugs and beyond

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish
Pages (from-to)199-200
Number of pages2
JournalAlimentary Pharmacology & Therapeutics
Issue number1
Publication statusPublished - 18 Dec 2019

Bibliographical note

Funding Information:
Declaration of personal interests : Dr Newsome reports consultancy/speaker fees on behalf of the University of Birmingham from Boehringer Ingelheim, Dignity Sciences, Gilead, Intercept, Johnson & Johnson, Novo Nordisk, Pfizer, Poxel Pharmaceuticals and Shire. His institution receives grant funding from Pharmaxis, Boehringer Ingelheim and Novo Nordisk. Dr Horn reports scientific collaboration with Novo Nordisk, Geratherm respiratory GmbH and UST Umweltsensortechnik and funding from Novo Nordisk.

Funding Information:
The authors' research is funded and supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the NHS.

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this